
Filippo Montemurro: Uncovering Actionable Targets in GATA3-Mutant HR+ Resistant Tumors
Filippo Montemurro, Senior Medical Director at Roche, shared a post on X about a paper by Arielle J. Medford et al. published in Breast Cancer Research and Treatment:
“Conoccurring mutations in GATA3 mutant tumors may reveal actionable targets in HR+ resistant tumors. Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes – PubMed.”
Title: Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes
Authors: Arielle J. Medford, Marko Velimirovic, Yifat Gefen, Andrzej Niemierko, Lorenzo Gerratana, Andrew A. Davis, Katherine Clifton, Jennifer Keenan, Emily Podany, Whitney L. Hensing, Carolina Reduzzi, Charles S. Dai, Lesli A. Kiedrowski, Laura M. Spring, Leif W. Ellisen, Robert C. Doebele, Massimo Cristofanilli, Gad Getz, Aditya Bardia
You can read the Full Article in Breast Cancer Research and Treatment.
More posts featuring Filippo Montemurro.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023